Connick, P; Kolappan, M; Crawley, C; Webber, DJ; Patani, R; Michell, AW; ... Chandran, S; + view all Connick, P; Kolappan, M; Crawley, C; Webber, DJ; Patani, R; Michell, AW; Du, MQ; Luan, SL; Altmann, DR; Thompson, AJ; Compston, A; Scott, MA; Miller, DH; Chandran, S; - view fewer (2012) Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol , 11 (2) 150 - 156. 10.1016/S1474-4422(11)70305-2.
Full text not available from this repository.
More than half of patients with multiple sclerosis have progressive disease characterised by accumulating disability. The absence of treatments for progressive multiple sclerosis represents a major unmet clinical need. On the basis of evidence that mesenchymal stem cells have a beneficial effect in acute and chronic animal models of multiple sclerosis, we aimed to assess the safety and efficacy of these cells as a potential neuroprotective treatment for secondary progressive multiple sclerosis.
|Title:||Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.|
|Additional information:||PMCID: PMC3279697|
|Keywords:||Adult, Feasibility Studies, Female, Humans, Infusions, Intravenous, Leukocytes, Mononuclear, Male, Mesenchymal Stem Cell Transplantation, Mesenchymal Stromal Cells, Middle Aged, Multiple Sclerosis, Chronic Progressive, Severity of Illness Index, Transplantation, Autologous, Treatment Outcome, Vision Disorders|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Neurology > IoN - Neuroinflammation|
UCL > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Neurology > Molecular Neuroscience
Archive Staff Only: edit this record